Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 1, 1998, Pages 1-6

  Or, Reuven ^a   Ackerstein, Aliza ^a   Nagler, Arnon ^a   Kapelushnik, Joseph ^a   Naparstek, Elizabeth ^a   Samuel, Simcha ^a   Amar, Avraham ^a   Bruatbar, Chaim ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic cell mediated therapy; Autologous stem cell transplantation; Breast cancer; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; MELPHALAN; RECOMBINANT INTERLEUKIN 2; THIOTEPA;

ADOPTIVE TRANSFER; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOTHERAPY; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL;

ADULT; ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHIMERA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MIDDLE AGED; NUCLEAR FAMILY; PILOT PROJECTS; RECOMBINANT PROTEINS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0031947634     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Mathe G, Amiel JL, Schwarzenberg L et al, Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res (1965) 25: 1525-31.
2. Horowitz MM, Gale RP, Sondel PM et al, Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 76: 555-62.
3. Soiffer RJ, Donor lymphocyte infusions: the door is open (editorial). J Clin Oncol (1997) 15: 416-7.
4. Collins RH Jr, Shpilberg O, Drobyski WR et al, Donor leucocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 15: 433-44.
5. Kolb HJ, Mittermuller J, Clemm C et al, Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76: 2462-5.
6. Slavin S, Naparstek E, Nagler A et al, Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood (1996) 87: 2195-204.
7. Slavin S, Ackerstein A, Weiss L et al, Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest (1992) 10: 221-7.
8. Weiss L, Lubin I, Factorowich Y et al, Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma (BCL1). Role of cell therapy and recombinant IL-2. J Immunol (1994) 153: 2562-7.
9. Dranoff G, Jaffee E, Lazenby A et al, Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA (1993) 90: 3539-43.
10. Mackinnon S, Papadopoulos EB, Carabasi MH et al, Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-host leukemia responses from graft-versus-host disease. Blood (1995) 86: 1261-8.
11. Slavin S, Ackerstein A, Naparstek E et al, The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant (1990) 6: 155-61.
12. + T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow. Bone Marrow Transplant (1991) 8: 51-8.
13. Jiang Y-Z, Cullies JO, Kanfer EJ et al, T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant (1993) 11: 133-8.
14. Sosman JA, Oettel KR, Smith SD et al, Specific recognition of human leukemic cells by allogeneic T cell lines. II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated non-leukemic cells. Blood (1990) 75: 2005-16
15. Milpied N, Fielding AK, Pearce RM et al, Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Marrow Transplantation J Clin Oncol (1996) 14: 1291-6.
16. Besien van KW, Mehra RC, Giralt SA et al, Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity, and survival depend on disease histology. Am J Med (1996) 100: 299-307.
17. Trico G, Vesole DH, Jagannath S et al, Graft-versus-myeloma effect: proof of principle. Blood (1996) 87: 1196-8.
18. Ratanatharathom V, Uberti J, Karanes C et al, Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood (1994) 84: 1050-5.
19. Anderson JE, Litzow MR, Appelbaum FR et al, Allogeneic, syngeneic, and autologous bone marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol (1993) 11: 2342-50.
20. Mendoza E, Territo M, Schiller G et al, Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant (1995) 15: 299-303.
21. Pugatsch T, Oppenheim A, Slavin S, Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant (1996) 17: 273-5.
22. Somlo G, Doroshow JH, Forman J et al, High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol (1997) 15: 2883-93.
23. Peters WP, Ross M, Vredenburgh JJ et al, High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol (1993) 11: 1132-43.
24. Antman K, Ayash L, Elias A et al, A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol (1992) 10: 102-10.
25. Bezwoda WR, Seymour L, Dansey RD, High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol (1995) 13: 2483-9.
26. Naparstek E, Or R, Nagler A et al, T-cell-depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol (1995) 89: 506-15.
27. Talmadge JE, The combination of stem cell transplantation and immunotherapy: future potential. In vivo (1994) 8: 675-90.
28. Kennedy MJ, Induced autologous graft-versus-host disease for the treatment of cancer. Cancer Treat Rev (1994) 20: 97-103.
29. Yeager AM, Vogelsang GB, Jones RJ et al, Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood (1992) 79: 3031-5.
30. Glazier A, Tutschka PJ, Farmer ER, Santos GW, Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med (1983) 158: 1-8
31. Gryn J, Johnson E, Goldmann N et al, The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant (1997) 19: 221-6.
32. Hortobaygi GN, Gutterman JU, Blumenschein GR et al, Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG, Cancer (1979) 43: 1225-33.
33. Guittermman JU, Blumenschein GR, Alexanian R et al, Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma. Ann Intern Med (1980) 93: 399-406.
34. Dollbaum C, Creasey AA, Dairkee SH et al, Specificity of tumor necrosis factor toxicity for human carcinoma relative to normal mammary epithelium and correlation with response to doxorubicin. Proc Natl Acad Sci USA (1988) 85: 4740-4.
35. Breitmeyer JB, Immunotherapy of breast cancer. In: Adjuvant Therapy of Breast Cancer (ed IC Henderson) 331-56. Kluwer, Dordrecht, 1992.
36. Rosenberg SA, Lotze MT, Muul LM et al, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 313: 1485-92.
37. Rosenberg SA, Lotze MT, Muul LM et al, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 316: 889-97.
38. Meloni G, Vignetti M, Andrizzi C et al, Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leuk Lymphoma (1996) 21: 429-35.
39. Klingemann H-G, Phillips GL, Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leuk Lymphoma (1995) 16: 397-405.
40. Ackerstein A, Kedar E, Slavin S, Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders. Blood (1991) 78: 1212-5.
41. Blaise D, Olive D, Stoppa AM et al, Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood (1990) 76: 1092-7.
42. Robbins PF, Kawakami Y, Human tumor antigens recognized by T cells. Curr Opin Immunol (1996) 8: 628-36.
43. Schlichtholz B, Legros Y, Gillet D, The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res (1992) 52: 6380-4.
44. Disis ML, Calenoff E, McLaughlin G et al, Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 54: 16-20.
45. Barnd DL, Lan MS, Metzgar RS, Finn OJ, Specific major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA (1989) 86: 7159-63.
46. Jerome KR, Barnd DL, Bendt KM et al, Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res (1991) 51: 2908-16.
47. Gimmi C, Morrison BW, Mainprice BA et al, Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med (1996) 2: 1367-70.
48. Boasberg P, Tokita KM, Terasaki PI, Wang X, Lymphocyte transfusion therapy for cancer patients Blood (1996) 87: 3522-3.
49. Eibl B, Schwaighofer H, Nachbaur D et al, Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood (1996) 88: 1501-8.
50. Kapelushnik J, Nagler A, Or R et al, Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation. Bone Marrow Transplant (1996) 18: 1153-6.
51. Sykes M, Abraham VS, Harty MW, Pearson DA, IL-2 reduces graft-versus-host disease and preserves CD4+ T cell activity. J Immunol (1993) 150: 197-205.
52. Sykes M, Harty MW, Szot GL, Pearson DA, Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects. Blood (1994) 83: 2560-9.
53. Sykes M, Pearson DA, Szot GL, IL-2-induced GVHD protection is not inhibited by cyclosporine and is maximal when IL-2 is given over a 25-h period beginning on the day following bone marrow transplantation. Bone Marrow Transplant (1995) 15: 395-9.
54. Slavin S, Naparstek E, Nagler A et al, Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT. Blood (1996) 97: 4011-3.
55. Slavin S, Naparstek E, Nagler A et al, Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol (1995) 23: 1553-62.
56. Cohen P, Vourka-Karussis U, Weiss L, Slavin S, Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. J Immunol (1993) 151: 4803-10.